AFMD Stock Overview
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$6.10|
|52 Week High||US$11.74|
|52 Week Low||US$4.78|
|1 Month Change||-9.76%|
|3 Month Change||-9.50%|
|1 Year Change||-9.90%|
|3 Year Change||70.39%|
|5 Year Change||205.00%|
|Change since IPO||7.02%|
Recent News & Updates
Affimed: Preparing For A Bullish 2022
Affimed reported mixed Q2 earnings that revealed more milestone payments from their partnerships. In addition, Affimed reported a healthy cash position that is expected to last into 2H of 2022. Affimed continues to move their wholly-owned and partnered pipeline programs. However, 2022 has several catalysts on the docket that could improve the company’s outlook. Despite the progress, the share price has remained under pressure and is moving closer to my buy area. Finally, I take a look at the charts to find a few opportunities to add to my "house money" position.
Does Affimed (NASDAQ:AFMD) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
|AFMD||US Biotechs||US Market|
Return vs Industry: AFMD underperformed the US Biotechs industry which returned -1.4% over the past year.
Return vs Market: AFMD underperformed the US Market which returned 16.5% over the past year.
|AFMD Average Weekly Movement||7.9%|
|Biotechs Industry Average Movement||8.9%|
|Market Average Movement||6.2%|
|10% most volatile stocks in US Market||14.8%|
|10% least volatile stocks in US Market||2.4%|
Stable Share Price: AFMD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: AFMD's weekly volatility (8%) has been stable over the past year.
About the Company
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. Its lead product candidate is AFM13, which has completed Phase II clinical study of CD30-positive T-cell lymphoma, and hodgkin lymphoma (HL), as well as is in Phase II clinical trials for peripheral T-cell lymphoma, and transformed mycosis fungoides; that is in Phase I clinical study in combination with adoptive NK cells for CD30-postive lymphomas; and has completed Phase Ib clinical study in combination with anti-PD-1 antibody Keytruda (pembrolizumab) in patients with relapsed HL. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase I/IIa clinical trials for the treatment of advanced cancer patients; and AFM26, an innate cell-engaging bispecific antibody targeting B cell maturation antigen (BCMA) for the treatment of multiple myeloma.
Affimed Fundamentals Summary
|AFMD fundamental statistics|
Is AFMD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AFMD income statement (TTM)|
|Cost of Revenue||€0|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.40|
|Net Profit Margin||-120.70%|
How did AFMD perform over the long term?See historical performance and comparison
Is Affimed undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AFMD's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AFMD's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AFMD is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: AFMD is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AFMD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AFMD is overvalued based on its PB Ratio (5x) compared to the US Biotechs industry average (2.6x).
How is Affimed forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AFMD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: AFMD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: AFMD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: AFMD's revenue (26.4% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: AFMD's revenue (26.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AFMD's Return on Equity is forecast to be high in 3 years time
How has Affimed performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: AFMD is currently unprofitable.
Growing Profit Margin: AFMD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: AFMD is unprofitable, and losses have increased over the past 5 years at a rate of 6.9% per year.
Accelerating Growth: Unable to compare AFMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AFMD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: AFMD has a negative Return on Equity (-36.84%), as it is currently unprofitable.
How is Affimed's financial position?
Financial Position Analysis
Short Term Liabilities: AFMD's short term assets (€203.3M) exceed its short term liabilities (€66.3M).
Long Term Liabilities: AFMD's short term assets (€203.3M) exceed its long term liabilities (€20.2M).
Debt to Equity History and Analysis
Debt Level: AFMD has more cash than its total debt.
Reducing Debt: AFMD's debt to equity ratio has reduced from 8.5% to 7.6% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: AFMD has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: AFMD has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 3.4% each year.
What is Affimed current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AFMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AFMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AFMD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AFMD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AFMD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Adi Hoess (60 yo)
Dr. Adi Hoess, M.D., Ph D., has been the Chief Executive Officer of Affimed N.V. since September 2011 and serves as its Managing Director and Member of Management Board. Dr. Hoess served as Chief Commercia...
CEO Compensation Analysis
Compensation vs Market: Adi's total compensation ($USD1.53M) is below average for companies of similar size in the US market ($USD2.35M).
Compensation vs Earnings: Adi's compensation has increased whilst the company is unprofitable.
Experienced Management: AFMD's management team is considered experienced (3 years average tenure).
Experienced Board: AFMD's board of directors are considered experienced (7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.4%.
Affimed N.V.'s employee growth, exchange listings and data sources
- Name: Affimed N.V.
- Ticker: AFMD
- Exchange: NasdaqGM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$750.893m
- Shares outstanding: 123.10m
- Website: https://www.affimed.com
Number of Employees
- Affimed N.V.
- Im Neuenheimer Feld 582
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/12/07 00:23|
|End of Day Share Price||2021/12/06 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.